A Study to Evaluate ARD-501 in Patients With Autism Spectrum Disorder

NCT06126653 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

5

Enrollment

INDUSTRY

Sponsor class

Conditions

Autism Spectrum Disorder

Interventions

DRUG: Low Dose ARD-501
DRUG: High Dose ARD-501
DRUG: Placebo

Sponsor

Aardvark Therapeutics, Inc.

Collaborators

[object Object]